Search results
292 Results for 'Donald E. Ingber'
- Technologies (24)
- Collaborations (2)
- Team (0)
- News (198)
- Pages (0)
- Multimedia (50)
- Publications (0)
- Jobs (0)
- Events (18)
Technologies 24
-
AminoX: Making Biologics Safer with Synthetic Biology and Advanced Chemistry
AminoX enables protein drugs to only become active in the tumor microenvironment and not elsewhere in the body to avoid immune-related adverse effects in the body. By designing and building non-standard amino acids into strategic positions of protein drugs, AminoX provides tumor-specific, and longer-lasting target inhibition. -
Plastivores: Plastic-Degrading Super-Microbes and Enzymes
The Plastic Degradation project identifies microbes from natural sources that have a low-level ability to degrade multiple types of plastic. In the laboratory, with the help of synthetic biology, those microbes then are evolved into much more effective plastic-eating microbes that, in the future, could be globally deployed to decompose plastic waste. -
FeCILL: Targeted Treatment for Severe Fungal Infections
FeCILL is novel delivery vehicle for antifungal drugs that targets them right to the infection site and reduces harmful side effects in patients with severe fungal infections. -
Ichor: Reversing Aging
Ichor is addressing multiple age-related diseases by identifying genetic interventions that reprogram old cells to a younger state. Therapies based on these interventions could improve survival for cancer patients and long-term cardiovascular and neurological health. -
Sugar-to-Fiber Enzyme for Healthier Food
In collaboration with Kraft Heinz, our sugar-to-fiber product can convert sugar in food products into prebiotic fiber in the human gut, reducing the amount of sugar absorbed into the bloodstream without altering the amount of sugar in existing food product recipes. -
eRapid: Multiplexed Electrochemical Detection of Complex Diseases
StataDX licensed the eRapid portable electrochemical sensing technology to develop diagnostics for neurological, cardiovascular, and renal diseases with a first focus on building a point-of-care platform for difficult-to-detect neurological disorders.
Collaborations 2
-
Kraft Heinz Partnership
The Kraft Heinz company approached the Wyss Institute for help to achieve its ambitious goal to make its food products healthier, resulting in a novel technology that is ripe for commercialization. -
Brain Targeting Program
Pre-competitive multi-partner industry collaboration that aims to identify novel transport targets and shuttle compounds to enable more effective delivery of drugs to the brain.
News 198
Multimedia 50
-
Video/AnimationBridging science, engineering, and art: from mechanobiology to Human Organs-on-ChipsIn this Marsilius Lecture, Wyss Founding Director Don Ingber shares his personal path from a serendipitous experience in an undergraduate art class that led to his discovery of how living cells are constructed using “tensegrity” architecture and how this contributed to the birth of the field of Mechanobiology to his more recent work on human... -
Video/AnimationNovel Model Organisms w/ Don Ingber & Hans Clevers – BIOS RoundtableDon Ingber – Founding Director at Wyss Institute Hans Clevers – Head of Pharma Research & Development (pRED) at Roche Hear about the evolution of humanized models and their potential applications in drug development, personalized medicine, and more. Ingber and Clevers share their scientific experiences and expertise. They also discuss misconceptions surrounding the application of... -
Video/AnimationFeCILL: Reimagining How We Treat the Sickest PatientsOpportunistic fungal infections usually only affect patients whose immune systems are compromised, but when they do, they are often deadly – the mortality rate for these infections can be as high as 25%. Existing antifungal treatments have high levels of toxicity, and can harm the patient more than they help. Researchers at the Wyss Institute... -
Video/AnimationInnovation Institutes w/ Don Ingber, David Baker, Brad Ringeisen, & Patrick Hsu – BIOS Roundtable #6Don Ingber – Founding Director at the Wyss Institute & Professor at Harvard Brad Ringeisen – Executive Director at Innovative Genomics Institute David Baker – Professor at UW & Director at Institute for Protein Design Patrick Hsu – Assistant Professor at UC Berkeley & Co-Founder at Arc Institute As the number of breakthrough biomedical discoveries... -
Audio/PodcastAnimal Free Labcast #4 – The PioneerWorld-class pioneer of biomedical research and innovation, Dr. Don Ingber, is the founding director of Harvard University’s Wyss Institute for Biologically Inspired Engineering. In 2010, Dr. Ingber developed a lung-on-a-chip – the first of its kind – and has continued to lead the field by developing numerous other organ chip models, demonstrating their ability to... -
Audio/PodcastPreventing the Next Pandemic with Organ ChipsIn search for strategies to curb pandemics, scientists strive to understand how pathogens slip past the immune system and wreak havoc on the body. To achieve this goal, researchers study viral infection in models that mimic how different cell types interact with each other, the immune system, or the environment. Organ-on-a-chip models combine tissue engineering...
Events 18
-
Jun 22, 2023, 11:00am - 12:00pmWebinar
- Add to Calendar
- iCalendar
- Google Calendar
- Outlook
Body-on-a-Chip technology is reshaping drug discovery, disease research, and personalized medicine. Please join a one-of-a-kind Ask Me Anything (AMA) session with the visionary behind it all: Donald Ingber. Prof. Ingber will be there, live, to answer YOUR questions and unveil the untapped potential of this groundbreaking technology. This is your chance to be part of... Free and open to public -
Mar 30, 2022, 1:00pm - 2:00pmWyss Event
- Add to Calendar
- iCalendar
- Google Calendar
- Outlook
Endothelial cells (ECs) are a heterogeneous and ductile cell type that serves as a critical interface between blood and diverse tissue microenvironments. ECs can adopt brain organotypic properties in response to their interaction a complex ecosystem of cells: adjacent mural smooth muscle cells and pericytes, perivascular immune cells, and surrounding astrocytes that differ across brain... Free and open to public -
Mar 3, 2021, 11:00am - 3:00pmLecture
- Add to Calendar
- iCalendar
- Google Calendar
- Outlook
Biologic drugs comprise 40 percent of the current drug development pipeline. Existing in vitro and animal models are limited in their ability to evaluate the safety and efficacy of these drugs in humans. These limitations often result in development delays and increased costs. Organs-on-chips emulate human biology by providing a micro-engineered environment lined with living... Free and open to public